Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia

Authors

Jason D. Maguire, United States Naval Medical Research Unit #2, Jakarta, IndonesiaFollow
Iwa W. Sumawinata, United States Naval Medical Research Unit #2, Jakarta, Indonesia
Sofyan Masbar, United States Naval Medical Research Unit #2, Jakarta, Indonesia
Budhi Laksana, United States Naval Medical Research Unit #2, Jakarta, Indonesia
Purnomo Prodjodipuro, United States Naval Medical Research Unit #2, Jakarta, Indonesia
Ika Susanti, United States Naval Medical Research Unit #2, Jakarta, Indonesia
Priyanto Sismadi, Indonesian Ministry of Health Institute of Health Research and Development, Jakarta
Nurlis Mahmud, District Health Service, Kalianda, Lampung Selatan, Sumatra
Michael J. Bangs, United States Naval Medical Research Unit #2, Jakarta, Indonesia
J. Kevin Baird, United States Naval Medical Research Unit #2, Jakarta, IndonesiaFollow

Date of this Version

2002

Citation

THE LANCET, Vol 360, July 6, 2002, www.thelancet.com

Comments

U.S. Government Work

Abstract

Oral chloroquine is the treatment of choice for uncomplicated Plasmodium malariae infections worldwide. We did a prospective 28-day in-vivo assessment of the efficacy of chloroquine for treatment of P malariae on Legundi Island in Lampung Bay, Sumatra, Indonesia. Of 28 patients, one had recurrent parasitaemia on day 28, and two had persistent parasitaemia to day 8. Whole-blood chloroquine and desethylchloroquine concentrations were at ordinarily effective levels (>100 µh/L) on day 8 in both cases of persistent parasitaemia. These findings suggest that clinical resistance to chloroquine by P malariae occurs in the Indonesian archipelago of southeast Asia.